AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37237172 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3368715 (100 mg)
Number of subjects: 31
Study 37237266 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipsin overexpression
Number of subjects: 0
Study 37237266 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipsin-enriched exosomes
Number of subjects: 0
Study 37237266 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipsin
Number of subjects: 0
Study 37237266 — intervention group
Group type: COMPARATOR
Intervention: Csk knockdown
Number of subjects: 0
Study 37237278 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task gait analysis using foot-worn inertial sensors
Number of subjects: 29
Study 37237278 — intervention group
Group type: COMPARATOR
Intervention: Single-task gait metrics
Number of subjects: 29
Study 37237278 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task effect on gait speed
Number of subjects: 29
Study 37237302 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-focused implementation strategies (n = 2 CACs)
Number of subjects: 4
Study 37237302 — intervention group
Group type: COMPARATOR
Intervention: Standard implementation (n = 2 CACs)
Number of subjects: 4
Study 37237339 — intervention group
Group type: EXPERIMENTAL
Intervention: Public-facing, tailored health communication intervention (LungTalk) via social media
Number of subjects: 0
Study 37237339 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37237405 — intervention group
Group type: EXPERIMENTAL
Intervention: Low hemoglobin at baseline (n=224)
Number of subjects: 1114
Study 37237405 — intervention group
Group type: COMPARATOR
Intervention: Normal hemoglobin at baseline (n=890)
Number of subjects: 1114
Study 37237416 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin, a recombinant analog of human leptin, administered as an adjunct to diet.
Number of subjects: 85
Study 37237425 — intervention group
Group type: EXPERIMENTAL
Intervention: DeSSBack (electronic clinical decision support system)
Number of subjects: 36
Study 37237425 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 36
Study 37239618 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation (20 g of whey protein isolate) with resistance training (RT) for 12 weeks, twice a week.
Number of subjects: 26
Study 37239618 — intervention group
Group type: COMPARATOR
Intervention: Control group received an isocaloric drink (20 g of maltodextrin) with resistance training (RT) for 12 weeks, twice a week.
Number of subjects: 26
Study 37239720 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application (LactApp) used in addition to usual clinical practice.
Number of subjects: 0
Study 37239720 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical practice (control group).
Number of subjects: 0
Study 37240667 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete response (UAS7 = 0)
Number of subjects: 382
Study 37240667 — intervention group
Group type: COMPARATOR
Intervention: UAS7 = 1-6 evaluations
Number of subjects: 382
Study 37242129 — intervention group
Group type: EXPERIMENTAL
Intervention: Aversive conditioning (lipid infusion via naso-duodenal catheter)
Number of subjects: 12
Study 37242129 — intervention group
Group type: COMPARATOR
Intervention: Sham conditioning (sham infusion)
Number of subjects: 12
Study 37242222 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants fed formula supplemented with 0.2 g/L 2'-FL + 2.2 g/L GOS
Number of subjects: 0
Study 37242222 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants fed formula supplemented with 1.0 g/L 2'-FL + 1.4 g/L GOS
Number of subjects: 0
Study 37242222 — intervention group
Group type: COMPARATOR
Intervention: Breastfed infants
Number of subjects: 0
Study 37242723 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release tacrolimus (TAC-IR)
Number of subjects: 23
Study 37242723 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release tacrolimus (TAC-LCP)
Number of subjects: 23
Study 37242723 — intervention group
Group type: COMPARATOR
Intervention: Whole blood tacrolimus concentrations
Number of subjects: 23
Study 37242723 — intervention group
Group type: COMPARATOR
Intervention: Calcineurin activity (CNA)
Number of subjects: 23
Study 37243171 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination (SARS-CoV-2 vaccine)
Number of subjects: 20
Study 37243171 — intervention group
Group type: COMPARATOR
Intervention: Control (unvaccinated patients with post-acute COVID-19)
Number of subjects: 20
Study 37243336 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus (15 mg/m weekly)
Number of subjects: 10
Study 37243345 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg PO BID (n = 20)
Number of subjects: 40
Study 37243345 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 40
Study 37243342 — intervention group
Group type: EXPERIMENTAL
Intervention: Stigma-related variables
Number of subjects: 637
Study 37243342 — intervention group
Group type: EXPERIMENTAL
Intervention: Affirming healthcare provision
Number of subjects: 637
Study 37243355 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox regression models for composite time-to-event endpoints with component-wise censoring
Number of subjects: 0
Study 37243446 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplantation
Number of subjects: 144
Study 37243446 — intervention group
Group type: EXPERIMENTAL
Intervention: Canonical metabolic markers (serum methylmalonic acid and propionylcarnitine)
Number of subjects: 144
Study 37243560 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential stimulation of the NAc-ALIC
Number of subjects: 13
Study 37243712 — intervention group
Group type: EXPERIMENTAL
Intervention: LL2643 quantitative polymerase chain reaction (qPCR)
Number of subjects: 53
Study 37243712 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of LL2643 in plasma-derived circulating cell-free DNA (ccfDNA)
Number of subjects: 53
Study 37243712 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of LL2643 ccfDNA post-treatment with diethylcarbamazine (DEC)
Number of subjects: 53
Study 37243712 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of LL2643 in urine
Number of subjects: 53
Study 37243941 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) defined as an apnea hypopnea index ≥ 15 events/h
Number of subjects: 1927
Study 37243954 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental increases in positive end-expiratory pressure (PEEP) to a maximum of 15 cmH2O
Number of subjects: 0
Study 37244205 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 0
Study 37244266 — intervention group
Group type: EXPERIMENTAL
Intervention: Befotertinib (75-100 mg once daily)
Number of subjects: 362
Study 37244266 — intervention group
Group type: COMPARATOR
Intervention: Icotinib (125 mg three times per day)
Number of subjects: 362
Study 37244360 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant boosts to 74 Gy total over 30 fractions
Number of subjects: 45
Study 37244360 — intervention group
Group type: COMPARATOR
Intervention: Standard 60 Gy radiation
Number of subjects: 45
Study 37244360 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton therapy
Number of subjects: 45
Study 37244360 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin-paclitaxel
Number of subjects: 45
Study 37244360 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper quartile decrease in SUVmean (>39.7%)
Number of subjects: 45
Study 37244366 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study 37244366 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 0
Study 37244365 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga group
Number of subjects: 168
Study 37244365 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise group
Number of subjects: 168
Study 37244365 — intervention group
Group type: COMPARATOR
Intervention: Stretching-toning active control group
Number of subjects: 168
Study 37244367 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief clinician-administered Skills Training in Affective and Interpersonal Regulation (Brief STAIR)
Number of subjects: 0
Study 37244367 — intervention group
Group type: EXPERIMENTAL
Intervention: web-administered STAIR (webSTAIR)
Number of subjects: 0
Study 37244454 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal estrogen (1 g conjugated estrogen intravaginal cream, 0.625 mg/g)
Number of subjects: 199
Study 37244454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 37244458 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 1384
Study 37244458 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal myomectomy
Number of subjects: 1384
Study 37244458 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy
Number of subjects: 1384
Study 37244458 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolization
Number of subjects: 1384
Study 37244626 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy with Simultaneous Integrated Boost
Number of subjects: 502
Study 37244626 — intervention group
Group type: COMPARATOR
Intervention: 3-Dimensional Conformal Radiation Therapy with Sequential Boost
Number of subjects: 502
Study 37244810 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap immunization in pregnant women
Number of subjects: 81
Study 37244942 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilized peripheral blood-derived hematopoietic stem/progenitor cells
Number of subjects: 13
Study 37244942 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow-derived hematopoietic stem/progenitor cells
Number of subjects: 13
Study 37245012 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic navigation bronchoscopy (ENB) performed under cone beam CT guidance (CBCT)
Number of subjects: 49
Study 37245012 — intervention group
Group type: COMPARATOR
Intervention: Electromagnetic navigation bronchoscopy (ENB) performed in a classical endoscopy suite
Number of subjects: 49
Study 37245012 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-bronchial lung cryobiopsy (TBLC) in addition to trans-bronchial biopsies (TBB)
Number of subjects: 49
Study 37245018 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (individual and group) in addition to standard treatment for 10 participants (6 weekly sessions)
Number of subjects: 15
Study 37245018 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment only for 5 participants (control group)
Number of subjects: 15
Study 37245030 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperhydration (200% maintenance balanced crystalloid fluids up to targets of 10% weight gain and 20% reduction in hematocrit)
Number of subjects: 1040
Study 37245030 — intervention group
Group type: COMPARATOR
Intervention: Conservative fluid management (in- or outpatients based on clinician preference, focused on close laboratory monitoring and maintenance of euvolemia)
Number of subjects: 1040
Study 37245041 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-facilitated telemedicine HCV care (peer tele-HCV)
Number of subjects: 0
Study 37245041 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 0
Study 37245042 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening algorithm based on primary care EHR data
Number of subjects: 30
Study 37245042 — intervention group
Group type: COMPARATOR
Intervention: Control group (58,223 patients)
Number of subjects: 30
Study 37245191 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose interleukin-2 (IL2)
Number of subjects: 0
Study 37245191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37245250 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol therapy
Number of subjects: 794
Study 37245250 — intervention group
Group type: COMPARATOR
Intervention: No β-blocker therapy
Number of subjects: 794
Study 37245331 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat/high-sugar diet (HFHS)
Number of subjects: 15
Study 37245331 — intervention group
Group type: COMPARATOR
Intervention: Low-fat/low-sugar diet
Number of subjects: 15
Study 37245522 — intervention group
Group type: EXPERIMENTAL
Intervention: CPX-351 (intravenous, 100 mg/m²)
Number of subjects: 31
Study 37245522 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 31
Study 37245517 — intervention group
Group type: EXPERIMENTAL
Intervention: Care bundle intervention including early intensive lowering of systolic blood pressure (target <140 mm Hg), strict glucose control (target 6·1-7·8 mmol/L for non-diabetics and 7·8-10·0 mmol/L for diabetics), antipyrexia treatment (target body temperature ≤37·5°C), and rapid reversal of warfarin-related anticoagulation (target INR <1·5) within 1 hour of treatment.
Number of subjects: 7036
Study 37245517 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (control).
Number of subjects: 7036
Study 37245660 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat density biomarker (calibrated fat intake)
Number of subjects: 81954
Study 37245660 — intervention group
Group type: COMPARATOR
Intervention: Fat density biomarker (calibrated fat intake) with control for additional dietary variables
Number of subjects: 81954
Study 37245855 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment Effectiveness Assessment (TEA)
Number of subjects: 403
Study 37245989 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (approved dose)
Number of subjects: 2540
Study 37246231 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP)
Number of subjects: 45
Study 37246242 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-warming (SW) blanket
Number of subjects: 150
Study 37246242 — intervention group
Group type: COMPARATOR
Intervention: Forced-air warming (FAW) blanket
Number of subjects: 150
Study 37246259 — intervention group
Group type: EXPERIMENTAL
Intervention: Live Attenuated Influenza Vaccine (LAIV)
Number of subjects: 320
Study 37246259 — intervention group
Group type: COMPARATOR
Intervention: Control (no LAIV)
Number of subjects: 320
Study 37246308 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual counseling with the PLISSIT model for 12 weeks after surgery
Number of subjects: 70
Study 37246308 — intervention group
Group type: COMPARATOR
Intervention: Routine postoperative care (control group)
Number of subjects: 70
Study 37246339 — intervention group
Group type: EXPERIMENTAL
Intervention: Care quality assessment for Black participants
Number of subjects: 701
Study 37246339 — intervention group
Group type: COMPARATOR
Intervention: Care quality assessment for White participants
Number of subjects: 701
Study 37246348 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab treatment
Number of subjects: 70
Study 37246588 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib discontinuation
Number of subjects: 84
Study 37246588 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib re-initiation after relapse
Number of subjects: 84
Study 37246588 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-treatment period
Number of subjects: 84
Study 37246632 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic risk scores (PRS) risk report
Number of subjects: 25000
Study 37246798 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study 37246953 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutimlimab
Number of subjects: 22
Study 37246998 — intervention group
Group type: EXPERIMENTAL
Intervention: NY104 PET tracer
Number of subjects: 3
Study 37247007 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural patients
Number of subjects: 36482
Study 37247089 — intervention group
Group type: EXPERIMENTAL
Intervention: Average Facebow Group (AFG)
Number of subjects: 14
Study 37247089 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional Facial Scan Group (PFG)
Number of subjects: 14
Study 37247089 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone Facial Scan Group (SFG)
Number of subjects: 14
Study 37247089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone-Beam Computed Tomography Group (CTG)
Number of subjects: 14
Study 37247089 — intervention group
Group type: EXPERIMENTAL
Intervention: Average Mounting Group (AMG)
Number of subjects: 14
Study 37247089 — intervention group
Group type: COMPARATOR
Intervention: Kinematic Facebow Group (KFG)
Number of subjects: 14
Study 37247166 — intervention group
Group type: EXPERIMENTAL
Intervention: SCT510 (3 mg/kg infusion)
Number of subjects: 84
Study 37247166 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (Avastin, 3 mg/kg infusion)
Number of subjects: 84
Study 37247190 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxelotor 1500 mg daily
Number of subjects: 10
Study 37247226 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 2584
Study 37247226 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 2584
Study 37247226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2584
Study 37247819 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotenoid group (10 mg L and 2 mg Z softgel)
Number of subjects: 47
Study 37247819 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo softgel)
Number of subjects: 47
Study 37247850 — intervention group
Group type: EXPERIMENTAL
Intervention: Active arm: animation including brief alcohol intervention (four minutes) and lifestyle health promotion (three minutes)
Number of subjects: 557
Study 37247850 — intervention group
Group type: COMPARATOR
Intervention: Control arm: lifestyle health promotion only
Number of subjects: 557
Study 37247850 — intervention group
Group type: EXPERIMENTAL
Intervention: Active arm
Number of subjects: 557
Study 37247850 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 557
Study 37247876 — intervention group
Group type: EXPERIMENTAL
Intervention: rhTNK-tPA 0.25 mg/kg (single bolus) to a maximum of 25 mg
Number of subjects: 100
Study 37247876 — intervention group
Group type: COMPARATOR
Intervention: standard medical therapy
Number of subjects: 100
Study 37247940 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental 16 min brachytherapy educational video (Arm B)
Number of subjects: 80
Study 37247940 — intervention group
Group type: COMPARATOR
Intervention: Standard informed consent (Arm A)
Number of subjects: 80
Study 37247957 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg oral prednisone daily for five consecutive days
Number of subjects: 456
Study 37247957 — intervention group
Group type: COMPARATOR
Intervention: Identical-appearing placebo (control group) for five consecutive days
Number of subjects: 456
Study 37247964 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural intervention involving a visuospatial task (BI-VT)
Number of subjects: 120
Study 37247964 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control Group (WCG)
Number of subjects: 120
Study 37248330 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified alteplase formulation (0.2 mg/kg body weight)
Number of subjects: 30
Study 37248330 — intervention group
Group type: EXPERIMENTAL
Intervention: Current alteplase formulation (0.2 mg/kg body weight)
Number of subjects: 30
Study 37248494 — intervention group
Group type: EXPERIMENTAL
Intervention: IB1001
Number of subjects: 0
Study 37248494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37248499 — intervention group
Group type: EXPERIMENTAL
Intervention: Hafnia alvei HA4597™ supplementation
Number of subjects: 0
Study 37248499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37248650 — intervention group
Group type: EXPERIMENTAL
Intervention: HUNT for HF risk score
Number of subjects: 36511
Study 37248650 — intervention group
Group type: COMPARATOR
Intervention: Existing HF risk scores (Health Aging and Body Composition HF risk score, Framingham HF risk score, Pooled Cohort equations to Prevent HF risk score, NORRISK 2)
Number of subjects: 36511
Study 37248808 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Eating Disorder Examination Questionnaire (PEDE-Q)
Number of subjects: 355
Study 37248808 — intervention group
Group type: COMPARATOR
Intervention: Eating Disorder Examination Questionnaire (EDE-Q)
Number of subjects: 355
Study 37248912 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamrevlumab (35-mg/kg intravenous infusions every 2 weeks for 2 years)
Number of subjects: 21
Study 37248912 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamrevlumab
Number of subjects: 21
Study 37249038 — intervention group
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab
Number of subjects: 0
Study 37249038 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab monotherapy
Number of subjects: 0
Study 37249422 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/XDR assay
Number of subjects: 497
Study 37249422 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolone-based all-oral shorter regimen
Number of subjects: 497
Study 37249422 — intervention group
Group type: COMPARATOR
Intervention: Injectable-containing regimen
Number of subjects: 497
Study 37249422 — intervention group
Group type: COMPARATOR
Intervention: Bedaquiline-based regimen
Number of subjects: 497
Study 37249512 — intervention group
Group type: EXPERIMENTAL
Intervention: YTB323 (autologous CD19-directed CAR T-cell therapy)
Number of subjects: 0
Study 37249512 — intervention group
Group type: COMPARATOR
Intervention: Tisagenlecleucel (traditional CAR T-cell therapy)
Number of subjects: 0
Study 37249619 — intervention group
Group type: EXPERIMENTAL
Intervention: BBT-176
Number of subjects: 2
Study 37249619 — intervention group
Group type: EXPERIMENTAL
Intervention: BBT-176 combined with cetuximab
Number of subjects: 2
Study 37249619 — intervention group
Group type: COMPARATOR
Intervention: Osimertinib
Number of subjects: 2
Study 37249646 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma Knife radiosurgery (GKRS)
Number of subjects: 92
Study 37249653 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined multi-view ultrasound variable
Number of subjects: 3532
Study 37249653 — intervention group
Group type: EXPERIMENTAL
Intervention: Single cIMT measurements
Number of subjects: 3532
Study 37249653 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque presence
Number of subjects: 3532
Study 37249653 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined multi-view ultrasound variable in 40-year olds
Number of subjects: 3532